CASE/0276/08/24 - Complainant v AstraZeneca

Allegations about an advertisement

  • Case number
    CASE/0276/08/24
  • Complaint received
    20 August 2024
  • Completed
    07 July 2025
  • Appeal hearing
    No appeal
  • Applicable Code year
    2021
  • No breach Clause(s)
  • Additional sanctions

Case Summary

This case was in relation to an advert for Ondexxya (andexanet alfa) on a website intended only for health professionals. The headline of the advert included a statement that Ondexxya was “NICE recommended”. The complainant alleged that this was misleading because it did not contain the full wording of the recommendation, which was that it was “recommended as an option”.

The outcome under the 2021 Code was:

No Breach of Clause 2

Requirement that activities or materials must not bring discredit upon, or reduce confidence in, the pharmaceutical industry

No Breach of Clause 5.1

 

Requirement to maintain high standards at all times

No Breach of Clause 6.1

 

Requirement that information/ claims/ comparisons must not be misleading

 

This summary is not intended to be read in isolation.
For full details, please see the full case report below.